A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 977 participants.

Also called NCT01294683

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 977 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01294683
  • EudraCT 2010-023939-42
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01294683. Randomized; double masking; primary purpose treatment. Start 2011-02-04 (actual); primary completion 2012-01-17 (actual). Results posted on 2016-12-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
Condition
Primary Hypercholesterolemia
Condition
Dyslipidemia
Intervention (Drug)
Simvastatin
Intervention (Drug)
Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)
Intervention (Drug)
Extended Release (ER) niacin/laropiprant (N/LRPT)
Intervention (Drug)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01294683
Content hash
2b769befbc78bd1f2b927ef36ac973e2bca087757d0eb81b519cb11dc55122b1